nct_id stringlengths 11 11 | title stringlengths 23 300 | phase stringclasses 9
values | status stringclasses 13
values | study_type stringclasses 2
values | is_expanded_access bool 2
classes | sponsor stringlengths 5 100 | summary stringlengths 45 4.76k | interventions listlengths 1 12 | start_date stringlengths 0 10 | url stringlengths 44 44 | target_entities listlengths 0 5 | locations listlengths 0 104 | contact_phone stringlengths 0 29 | contact_email stringlengths 0 41 | eligibility dict | mechanism_summary dict |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
NCT03613038 | A Systematic Investigation of Phonetic Complexity Effects on Articulatory Motor Performance in Progressive Dysarthria | NA | COMPLETED | INTERVENTIONAL | false | University of Missouri-Columbia | The goal is to improve the fundamental knowledge about articulatory motor performance in people with Lou Gehrig's disease (also known as ALS) and Parkinson's disease (PD), in order to develop more sensitive assessments for progressive speech loss, which may lead to the improved timing of speech therapies. | [
{
"type": "BEHAVIORAL",
"name": "Phonetic complexity effects on speech motor performance"
}
] | 2017-07-15 | https://clinicaltrials.gov/study/NCT03613038 | [] | [
{
"facility": "University of Kansas Medical Center",
"city": "Fairway",
"state": "Kansas",
"country": "United States",
"status": "",
"lat": 39.02223,
"lon": -94.6319
},
{
"facility": "University of Missouri-Columbia",
"city": "Columbia",
"state": "Missouri",
"country"... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05683860 | Open-label Extension (OLE) Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) and/or Frontotemporal Dementia (FTD) | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Wave Life Sciences USA, Inc. | This is an OLE study conducted to evaluate the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD), and clinical effects of WVE-004 in adult participants with ALS, FTD, or mixed ALS/FTD phenotype with a documented mutation in the C9orf72 gene. To participate in the study, participants must have successfu... | [
{
"type": "DRUG",
"name": "WVE-004 10 mg Q12W"
}
] | 2022-12-14 | https://clinicaltrials.gov/study/NCT05683860 | [
"C9orf72"
] | [
{
"facility": "Erasmus MC",
"city": "Rotterdam",
"state": "",
"country": "Netherlands",
"status": "",
"lat": 51.9225,
"lon": 4.47917
},
{
"facility": "Universitair Medisch Centrum Utrecht",
"city": "Utrecht",
"state": "",
"country": "Netherlands",
"status": "",
... | null | {
"compound": "WVE-004",
"targeting_mechanism": "WVE-004 targets the C9orf72 hexanucleotide repeat expansion through antisense oligonucleotide-mediated reduction of C9orf72 repeat transcripts in C9-ALS/FTD patients.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"r... | ||
NCT05995782 | A Phase 1, SAD and MAD Study to Evaluate the Safety and Tolerability of FB418 | PHASE1 | RECRUITING | INTERVENTIONAL | false | 1ST Biotherapeutics, Inc. | The purpose of this study is to evaluate the safety, tolerability and pharmacokinetics and pharmacodynamics of oral doses of FB418 in healthy adult subjects and healthy elderly subjects. | [
{
"type": "DRUG",
"name": "FB418"
}
] | 2023-12-20 | https://clinicaltrials.gov/study/NCT05995782 | [] | [
{
"facility": "Seoul National University",
"city": "Seoul",
"state": "",
"country": "South Korea",
"status": "RECRUITING",
"lat": 37.566,
"lon": 126.9784
}
] | +82-31-895-4677 | info@1stbio.com | null | {
"compound": "FB418",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07142291 | PHENOGENE-1A (Cromolyn) Treatment in Patients With Mild to Moderate ALS | PHASE2 | RECRUITING | INTERVENTIONAL | false | PhenoNet, Inc. | The purpose of this study is to test the effects of PHENOGENE-1A, which is the treatment under investigation in this study. This research will investigate if PHENOGENE-1A can help people with ALS by measuring their function using the ALS Functional Rating Scale Revised (ALSFRS-R), measuring lung function using pulmonar... | [
{
"type": "DRUG",
"name": "Cromolyn Sodium (34.2 mg BID)"
},
{
"type": "DRUG",
"name": "Cromolyn Sodium (17.1 mg BID)"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Riluzole (100 mg)"
}
] | 2025-11-25 | https://clinicaltrials.gov/study/NCT07142291 | [
"mast_cell_activation"
] | [
{
"facility": "Honor Health Neurology - Bob Bove Neuroscience Institute",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "RECRUITING",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "University of California San Diego",
"city": "La Jolla"... | +1 (617) 784-0490 | delmaleh@phenonet.us | null | {
"compound": "Cromolyn Sodium",
"targeting_mechanism": "Cromolyn sodium acts as a mast cell stabilizer and neuroprotective agent.",
"targeting_mechanism_pmid": "",
"animal_results": "Cromolyn sodium delayed disease onset and demonstrated neuroprotection in the SOD1(G93A) mouse model of amyotrophic lateral scle... |
NCT05136885 | HEALEY ALS Platform Trial - Regimen E SLS-005 - Trehalose | PHASE2, PHASE3 | COMPLETED | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS.
Regimen E will evaluate the safety and efficacy of a single study drug, SLS-005 (Trehalose injection, 90.5 mg/mL for intravenous infusion) in ... | [
{
"type": "DRUG",
"name": "SLS-005"
},
{
"type": "DRUG",
"name": "Matching Placebo"
}
] | 2022-02-21 | https://clinicaltrials.gov/study/NCT05136885 | [
"autophagy_impairment"
] | [
{
"facility": "Healey Center for ALS at Mass General",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | null | {
"compound": "SLS-005 (Trehalose)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04681118 | Expanded Access Protocol: Repeated Administration of Nurown® (Autologous MSC-NTF Cells) for the Treatment of ALS | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Brainstorm-Cell Therapeutics | Expanded Access for treatment with investigational product MSC-NTF cells(NurOwn®) for participants who completed all scheduled treatments and follow-up assessments in the BCT-002-US study | [
{
"type": "BIOLOGICAL",
"name": "NurOwn (MSC-NTF cells)"
}
] | https://clinicaltrials.gov/study/NCT04681118 | [
"neurotrophic_factors"
] | [
{
"facility": "University of California Irvine Alpha Stem Cell Clinic",
"city": "Irvine",
"state": "California",
"country": "United States",
"status": "",
"lat": 33.66946,
"lon": -117.82311
},
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"st... | null | {
"compound": "NurOwn (MSC-NTF cells)",
"targeting_mechanism": "Mesenchymal stem cells secreting neurotrophic factors to support motor neuron survival and function",
"targeting_mechanism_pmid": "",
"animal_results": "Preclinical stem cell studies in mouse and rat ALS models expressing mutant superoxide dismutas... | |||
NCT00116558 | Early Treatment of Amyotrophic Lateral Sclerosis (ALS) With Nutrition and Non-Invasive Positive Pressure Ventilation | NA | COMPLETED | INTERVENTIONAL | false | Edward Kasaraskis | The purposes of the study are to determine the energy balance and evaluate the nutritional status of patients with ALS, and to investigate the use of NIPPV as respiratory support to treat patients with ALS. | [
{
"type": "DEVICE",
"name": "Early NIPPV"
},
{
"type": "DEVICE",
"name": "Standard NIPPV"
}
] | 2004-08-01 | https://clinicaltrials.gov/study/NCT00116558 | [] | [
{
"facility": "University of Colorado",
"city": "Denver",
"state": "Colorado",
"country": "United States",
"status": "",
"lat": 39.73915,
"lon": -104.9847
},
{
"facility": "University of Miami",
"city": "Miami",
"state": "Florida",
"country": "United States",
"sta... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01771640 | Intrathecal Transplantation of Mesenchymal Stem Cell in Patients With ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Royan Institute | ALS is a debilitating disease with varied etiology characterized by rapidly progressive weakness, muscle atrophy and fasciculations, muscle spasticity, difficulty speaking (dysarthria), difficulty swallowing (dysphagia), and difficulty breathing (dyspnea). ALS is the most common of the five motor neuron diseases.Riluzo... | [
{
"type": "BIOLOGICAL",
"name": "intrathecal injection"
}
] | 2013-08 | https://clinicaltrials.gov/study/NCT01771640 | [
"neurotrophic_factors"
] | [
{
"facility": "Royan Institute",
"city": "Tehran",
"state": "",
"country": "Iran",
"status": "",
"lat": 35.69439,
"lon": 51.42151
}
] | null | {
"compound": "Mesenchymal stem cells",
"targeting_mechanism": "Intrathecal injection of mesenchymal stem cells to support motor neuron survival and function",
"targeting_mechanism_pmid": "",
"animal_results": "In SOD1 rat lumbar spinal cord, intrathecal injection of neural progenitor cells secreting GDNF at va... | ||
NCT04894240 | A Study of Monepantel in Individuals With Motor Neurone Disease | PHASE1 | COMPLETED | INTERVENTIONAL | false | Neurizon Therapeutics Limited | Amyotrophic lateral sclerosis/ Motor Neurone Disease (ALS/MND) is a rare and invariably fatal neurological disease. ALS/MND has a terribly high burden on patients, family and carers, and carries great socioeconomic burden. Current best treatment options are expensive and attempt to control disease progression and manag... | [
{
"type": "DRUG",
"name": "Monepantel"
}
] | 2022-06-28 | https://clinicaltrials.gov/study/NCT04894240 | [
"Myostatin"
] | [
{
"facility": "Macquarie University",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.86785,
"lon": 151.20732
},
{
"facility": "Calvary Health Care Bethlehem",
"city": "Melbourne",
"state": "Victoria",
"country": "Austral... | null | {
"compound": "Monepantel",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT01123200 | An In-home Study of Brain Computer Interfaces | NA | COMPLETED | INTERVENTIONAL | false | University of Michigan | The investigators are developing a tool to help people who are severely paralyzed. This tool is called a brain-computer interface (BCI). BCIs can connect to computers or other electronic devices.
This study allows a person with ALS to communicate, control their wheelchair tilt and perform other tasks using a BCI, thus... | [
{
"type": "DEVICE",
"name": "Brain Computer Interface for Wheelchair Tilt Control"
}
] | 2010-01 | https://clinicaltrials.gov/study/NCT01123200 | [] | [
{
"facility": "University of Michigan",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT05753852 | Open Label Extension of TUDCA-ALS Study | PHASE3 | UNKNOWN | INTERVENTIONAL | false | Humanitas Mirasole SpA | This study will provide extended access to patients and assess longer-term outcomes on patients who have completed the TUDCA-ALS study. | [
{
"type": "DRUG",
"name": "Tauroursodeoxycholic Acid"
}
] | 2021-10-25 | https://clinicaltrials.gov/study/NCT05753852 | [
"apoptosis"
] | [
{
"facility": "Katholieke Universiteit Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "ACTIVE_NOT_RECRUITING",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Centre Hospitalier Universitaire de Bordeaux",
"city": "Bordeaux",
"state": "",
"c... | +39-0282246418 | alberto.albanese@humanitas.it | null | {
"compound": "Tauroursodeoxycholic Acid",
"targeting_mechanism": "Tauroursodeoxycholic acid exerts anti-apoptotic and neuroprotective activities by inhibiting apoptosis in neurodegenerative diseases.",
"targeting_mechanism_pmid": "35659112",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurpos... |
NCT04505358 | Evaluate PU-AD in Subjects With Amyotrophic Lateral Sclerosis | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Samus Therapeutics, Inc. | This is a multicenter, Phase 2a, randomized, double-blind, placebo-controlled pilot study to assess the biological activity, safety and pharmacokinetics of PU-AD compared to placebo in ALS. It will be conducted in approximately 20 sites in the US. Approximately 30 subjects will be enrolled in this study; subjects will ... | [
{
"type": "DRUG",
"name": "PU-AD"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2023-01 | https://clinicaltrials.gov/study/NCT04505358 | [
"neuroinflammation"
] | [] | null | {
"compound": "PU-AD",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03694132 | Brain Excitability and Connectivity in Sensory-motor Pathways in ALS | NA | COMPLETED | INTERVENTIONAL | false | Institut National de la Santé Et de la Recherche Médicale, France | The main objective is to determine the origin of somatosensory alteration in patients with ALS and to evaluate its impact on brain activity by coupling different imaging modalities and indirect electrophysiology.
The secondary objective is to evaluate whether the observed functional changes in MEG / EEG and functional... | [
{
"type": "DEVICE",
"name": "functional MRI"
},
{
"type": "DEVICE",
"name": "structural MRI"
},
{
"type": "DEVICE",
"name": "EEG/MEG"
}
] | 2018-11-26 | https://clinicaltrials.gov/study/NCT03694132 | [] | [
{
"facility": "Hopital Pitie-Salpetriere",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03487263 | Dose-Escalation, Safety and Pharmacokinetic Study of IC14 in Motor Neurone Disease | PHASE1 | COMPLETED | INTERVENTIONAL | false | Implicit Bioscience | Ten patients with motor neurone disease (MND, also known as amyotrophic lateral sclerosis or ALS) will be successively enrolled to one of two dose levels of IC14 (human chimeric monoclonal anti-CD14) intravenously for four doses. Patients must be within 3 years of MND diagnosis and have adequate respiratory function. S... | [
{
"type": "BIOLOGICAL",
"name": "IC14"
}
] | 2017-10-01 | https://clinicaltrials.gov/study/NCT03487263 | [
"CD14"
] | [
{
"facility": "Royal Brisbane and Women's Hospital",
"city": "Herston",
"state": "Queensland",
"country": "Australia",
"status": "",
"lat": -27.44453,
"lon": 153.01852
}
] | null | {
"compound": "IC14",
"targeting_mechanism": "IC14 is a human chimeric monoclonal antibody targeting CD14.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06782958 | Safety, Tolerability, and Pharmacokinetics of FHND1002 Granules in Healthy Adults | PHASE1 | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | Jiangsu Chia Tai Fenghai Pharmaceutical Co., Ltd. | The goal of this clinical trial is to evaluate the safety, tolerability, and pharmacokinetic (PK) profile of FHND1002 granules in healthy adult volunteers. The study will also assess how a high-fat meal affects the PK characteristics of FHND1002.
The main questions this study aims to answer are:
What are the safety a... | [
{
"type": "DRUG",
"name": "50mg FHND1002"
},
{
"type": "DRUG",
"name": "100mg FHND1002"
},
{
"type": "DRUG",
"name": "150 mg FHND1002"
},
{
"type": "DRUG",
"name": "200 mg FHND1002（fasting）"
},
{
"type": "DRUG",
"name": "250mg FHND1002"
},
{
"type": "D... | 2024-07-05 | https://clinicaltrials.gov/study/NCT06782958 | [] | [
{
"facility": "The first hospital of Lanzhou University",
"city": "Lanzhou",
"state": "Gansu",
"country": "China",
"status": "",
"lat": 36.05701,
"lon": 103.83987
}
] | null | {
"compound": "FHND1002",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07174492 | Efficacy and Safety of Masitinib in Combination With SoC Versus Placebo in the Treatment of ALS Patients | PHASE3 | NOT_YET_RECRUITING | INTERVENTIONAL | false | AB Science | The objective is to compare the efficacy and safety of masitinib in combination with riluzole versus matched placebo in combination with riluzole for the treatment of Amyotrophic Lateral Sclerosis (ALS). | [
{
"type": "DRUG",
"name": "Masitinib 4.5 mg/kg/day"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "Riluzole (100 mg)"
}
] | 2026-01-01 | https://clinicaltrials.gov/study/NCT07174492 | [
"C-KIT",
"PDGFRA"
] | [
{
"facility": "Aiginition Hospital",
"city": "Athens",
"state": "",
"country": "Greece",
"status": "",
"lat": 37.98376,
"lon": 23.72784
}
] | +33(0)147200014 | clinical@ab-science.com | null | {
"compound": "Masitinib",
"targeting_mechanism": "Tyrosine kinase inhibitor that abrogates neuroinflammation and microgliosis",
"targeting_mechanism_pmid": "27400786",
"animal_results": "Masitinib significantly prolonged survival in SOD1G93A rats when delivered after paralysis onset, controlling microgliosis, ... |
NCT04875949 | Anti-Cholinergic Receptors Antibodies, Autonomic Profile and Dysautonomia Symptoms in PAF, ALS and POTS (DISAUT-AB) | NA | COMPLETED | INTERVENTIONAL | false | Istituto Clinico Humanitas | Anti alfa-3 and alfa-7 ganglionic cholinergic receptors (anti-AChRs) antibodies (Abs) plasma removal by plasmapheresis (1,2) acutely improved dysautonomia symptoms in case reports with Pure Autonomic Failure (PAF) (3). We shall assess the prevalence of anti-AChRs Ab and the relationship among Ab titer, cardiovascular a... | [
{
"type": "PROCEDURE",
"name": "Immunoabsorption/plasmapheresis procedure"
}
] | 2016-04 | https://clinicaltrials.gov/study/NCT04875949 | [
"cholinergic_receptors"
] | [
{
"facility": "Humanitas Research Hospital",
"city": "Rozzano",
"state": "",
"country": "Italy",
"status": "",
"lat": 45.38193,
"lon": 9.1559
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05981040 | Efficacy, Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of ZYIL1 in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Zydus Lifesciences Limited | ZYIL1 is expected to show benefit in patients with Amyotrophic Lateral Sclerosis (ALS). The present study aims to determine the safety, tolerability, pharmacokinetics, and pharmacodynamics of ZYIL1 when administered to subjects with ALS. | [
{
"type": "DRUG",
"name": "ZYIL1 capsules 25 mg and 50 mg Placebo"
},
{
"type": "DRUG",
"name": "ZYIL1 capsules 50 mg and 25 mg Placebo"
},
{
"type": "DRUG",
"name": "ZYIL1 capsules 25 mg and ZYIL1 capsules 50 mg"
},
{
"type": "DRUG",
"name": "Matching placebo 25 mg and M... | 2023-11-09 | https://clinicaltrials.gov/study/NCT05981040 | [] | [
{
"facility": "Zydus Hospitals & Healthcare Research",
"city": "Ahmedabad",
"state": "Gujarat",
"country": "India",
"status": "",
"lat": 23.02579,
"lon": 72.58727
},
{
"facility": "Rhythm heart institute",
"city": "Vadodara",
"state": "Gujarat",
"country": "India",
... | null | {
"compound": "ZYIL1",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07295990 | Tongue-strengthening Exercises in People With ALS. | NA | RECRUITING | INTERVENTIONAL | false | Nova Southeastern University | This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by comparing each person's results to their own earlier results.
People who join the study will hav... | [
{
"type": "PROCEDURE",
"name": "Isometric Lingual Strength Exercises"
}
] | 2026-05-01 | https://clinicaltrials.gov/study/NCT07295990 | [] | [
{
"facility": "Nova Southeastern University",
"city": "Davie",
"state": "Florida",
"country": "United States",
"status": "RECRUITING",
"lat": 26.06287,
"lon": -80.2331
}
] | 17863994053 | rw602@nova.edu | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT06441682 | A Safety and Efficacy Study of ARGX-119 in Adult Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | argenx | This study aims to evaluate the safety of ARGX-119 in adults with ALS. The study will also assess the impact of ARGX-119 on ALS disease outcomes, including muscle function. The study consists of 2 periods: a treatment period when participants will receive one of three ARGX-119 doses or placebo and an extension period w... | [
{
"type": "BIOLOGICAL",
"name": "ARGX-119"
},
{
"type": "OTHER",
"name": "Placebo"
}
] | 2024-10-23 | https://clinicaltrials.gov/study/NCT06441682 | [
"neuroinflammation"
] | [
{
"facility": "UZ Leuven",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "Kaye Edmonton Clinic",
"city": "Edmonton",
"state": "",
"country": "Canada",
"status": "",
"lat": 53.55014,
"lon... | null | {
"compound": "ARGX-119",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05633459 | A Study Evaluating the Safety and Tolerability of QRL-201 in ALS | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | QurAlis Corporation | The primary objective of this study is to determine the safety and tolerability of multiple doses of QRL-201 in people living with ALS | [
{
"type": "DRUG",
"name": "Multiple ascending doses of QRL-201"
},
{
"type": "DRUG",
"name": "Multiple ascending doses of Placebo"
},
{
"type": "DRUG",
"name": "QRL-201"
},
{
"type": "DRUG",
"name": "Placebo"
},
{
"type": "DRUG",
"name": "QRL-201"
}
] | 2022-12-16 | https://clinicaltrials.gov/study/NCT05633459 | [
"qrl_201"
] | [
{
"facility": "Universitaire Ziekenhuizen Leuven (UZ Leuven)",
"city": "Leuven",
"state": "",
"country": "Belgium",
"status": "",
"lat": 50.87959,
"lon": 4.70093
},
{
"facility": "University of Calgary",
"city": "Calgary",
"state": "Alberta",
"country": "Canada",
... | null | {
"compound": "QRL-201",
"targeting_mechanism": "Transplantation of human neural progenitor cells secreting GDNF to provide neuroprotection to motor neurons.",
"targeting_mechanism_pmid": "36064599",
"animal_results": "In SOD1 rat models, injections of CNS10-NPC-GDNF at doses of 10,000 to 250,000 cells were wel... | ||
NCT02478450 | Study to Investigate the Safety of the Transplantation (by Injection) of Human Glial Restricted Progenitor Cells (hGRPs; Q-Cells®) Into Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Q Therapeutics, Inc. | This study is a non-randomized, open-label, partially blinded, sequential cohort, dose-escalation study designed to obtain preliminary data on the safety, tolerability, and early efficacy of Q-Cells® transplantation in subjects with ALS. Following an initial cohort receiving cell transplants unilaterally in the lumbar ... | [
{
"type": "BIOLOGICAL",
"name": "Q-Cells"
}
] | 2026-12 | https://clinicaltrials.gov/study/NCT02478450 | [
"glial_restricted_progenitor_cells"
] | [] | null | {
"compound": "Q-Cells (human glial restricted progenitor cells, hGRPs)",
"targeting_mechanism": "Transplantation of human glial restricted progenitor cells into the spinal cord to support motor neuron survival and function.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid":... | ||
NCT04391361 | The Safety and Effectiveness of Cholinergic Receptor Block Therapy in the Treatment of ALS | PHASE2 | UNKNOWN | INTERVENTIONAL | false | Ruijin Hospital | Thirty cases of amyotrophic lateral sclerosis patients were recruited from the neurology department of Ruijin Hospital, the pain department and the encephalopathy center of Luwan Branch of Ruijin Hospital. After the informed consent was signed, they were divided into a trial group and a control group. Each group contai... | [
{
"type": "DRUG",
"name": "Scopolamine, atropine, edaravone and dexmedetomidine"
},
{
"type": "DRUG",
"name": "Edaravone"
}
] | 2020-11-01 | https://clinicaltrials.gov/study/NCT04391361 | [
"cholinergic_signaling",
"oxidative_stress"
] | [
{
"facility": "Department of neurology, Ruijin Hospital, Shanghai Jiao Tong University School of Medicine",
"city": "Shanghai",
"state": "Shanghai Municipality",
"country": "China",
"status": "",
"lat": 31.22222,
"lon": 121.45806
}
] | 64370045 | jly0520@hotmail.com | null | {
"compound": "scopolamine and atropine (cholinergic receptor blockers) plus edaravone and dexmedetomidine",
"targeting_mechanism": "Edaravone is a free radical scavenger that quenches hydroxyl radicals and inhibits lipid peroxidation to reduce oxidative stress in ALS.",
"targeting_mechanism_pmid": "38474192",
... |
NCT00790582 | A Multi-Center Controlled Screening Trial of Safety and Efficacy of Lithium Carbonate in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Forbes Norris MDA/ALS Research Center | This is a Phase II screening study of lithium carbonate in ALS. The purpose of this study is to find out if lithium carbonate is safe to be used in people with ALS and if it can slow the progression of the disease. Since there is no placebo in this study, all patients will be taking lithium carbonate. | [
{
"type": "DRUG",
"name": "lithium carbonate"
}
] | 2008-05 | https://clinicaltrials.gov/study/NCT00790582 | [
"lithium_carbonate"
] | [
{
"facility": "Mayo Clinic",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "UCLA Neuromuscular Research Center",
"city": "Los Angeles",
"state": "California",
"country": "United ... | null | {
"compound": "lithium carbonate",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07491562 | Evaluation of a Structurally Suitable Neck Exoskeleton in Patients With Amyotrophic Lateral Sclerosis | NA | RECRUITING | INTERVENTIONAL | false | University of Utah | The investigators will evaluate a new powered neck exoskeleton in patients with amyotrophic lateral sclerosis (ALS) to understand whether this device allows adequate head range of motion and achieves satisfaction from users. In this small cross-sectional device feasibility study, participants will be enrolled from the ... | [
{
"type": "DEVICE",
"name": "powered neck exoskeleton"
}
] | 2024-09-06 | https://clinicaltrials.gov/study/NCT07491562 | [] | [
{
"facility": "University of Utah",
"city": "Salt Lake City",
"state": "Utah",
"country": "United States",
"status": "RECRUITING",
"lat": 40.76078,
"lon": -111.89105
}
] | 801-585-2536 | haohan.zhang@utah.edu | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT00956488 | Supported Treadmill Ambulation Training (STAT) for Patients Diagnosed With Amyotrophic Lateral Aclerosis | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Wake Forest University Health Sciences | The purpose of this study is to find out if supervised exercise training using a treadmill with partial weight support is safe and has an impact on gait and function of persons with Amyotrophic lateral sclerosis. | [
{
"type": "BEHAVIORAL",
"name": "Treadmill Exercise"
}
] | 2008-09 | https://clinicaltrials.gov/study/NCT00956488 | [] | [
{
"facility": "Carolinas ALS Clinical Resarch Center",
"city": "Charlotte",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.22709,
"lon": -80.84313
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03113630 | Virtual Task in Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University of Sao Paulo | Thirty individuals with ALS (18 men and 12 women, mean age 59 years, range 44-74 years), and 30 healthy controls matched for age and gender, participated. Individuals with ALS and from the control group were randomly divided into three groups, each using a different communication device systems (Kinect®, Leap Motion Co... | [
{
"type": "DEVICE",
"name": "Acquisition on TouchScreen"
},
{
"type": "DEVICE",
"name": "Acquisition on Kinect"
},
{
"type": "DEVICE",
"name": "Acquisition on LeapMotion"
},
{
"type": "DEVICE",
"name": "Acquisition on TouchScreen Control Group"
},
{
"type": "DEVIC... | 2016-02-02 | https://clinicaltrials.gov/study/NCT03113630 | [] | [
{
"facility": "Escola de Artes,Ciencias e Humanidades da Universidade d Sao Paulo",
"city": "São Paulo",
"state": "São Paulo",
"country": "Brazil",
"status": "",
"lat": -23.5475,
"lon": -46.63611
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03085706 | Transplantation of Autologous Peripheral Blood Mononuclear Cells for Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | The First Affiliated Hospital of Dalian Medical University | To assess the safety of peripheral blood mononuclear cell transplantation into the subarachnoid space for the treatment of amyotrophic lateral sclerosis. | [
{
"type": "BIOLOGICAL",
"name": "PBMC autotransplantation"
}
] | 2010-10 | https://clinicaltrials.gov/study/NCT03085706 | [
"neuroinflammation"
] | [
{
"facility": "The First Affiliated Hospital of Dalian Medical University",
"city": "Dalian",
"state": "Liaoning",
"country": "China",
"status": "",
"lat": 38.91222,
"lon": 121.60222
}
] | null | {
"compound": "Peripheral blood mononuclear cells (PBMC)",
"targeting_mechanism": "Modulation of neuroinflammation through immune cell transplantation into the subarachnoid space.",
"targeting_mechanism_pmid": "37433768",
"animal_results": "Preclinical stem cell studies in mouse and rat ALS models expressing mu... | ||
NCT06249867 | A Study to Assess the Safety, Tolerability, and Pharmacology of Darifenacin in Patients With ALS | PHASE2 | RECRUITING | INTERVENTIONAL | false | Oliver Blanchard | Amyotrophic lateral sclerosis (ALS) is a progressive neurological disorder characterized by selective death of upper and lower motor neurons, which leads to severe disability and fatal outcomes. One of the major hallmarks of ALS is the denervation of neuromuscular junctions (NMJs), which is one of the earliest events s... | [
{
"type": "DRUG",
"name": "Darifenacin 7.5 MG Extended Release Oral Tablet"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2024-11-08 | https://clinicaltrials.gov/study/NCT06249867 | [
"Muscarinic acetylcholine receptor"
] | [
{
"facility": "Ottawa Hospital Research Institute",
"city": "Ottawa",
"state": "Ontario",
"country": "Canada",
"status": "RECRUITING",
"lat": 45.41117,
"lon": -75.69812
},
{
"facility": "Montreal Neurological Institute",
"city": "Montreal",
"state": "Quebec",
"country... | 514-396-2401 | nisha.pulimood@mcgill.ca | null | {
"compound": "Darifenacin",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "Adeno-associated virus-delivered artificial microRNA extended survival and delayed paralysis in SOD1G93A mouse model of ALS.",
"animal_results_pmid": "26891182",
"repurposed_from": "unknown",
... |
NCT03836716 | Arimoclomol in Amyotropic Lateral Sclerosis - Open Label Extension Trial | PHASE3 | TERMINATED | INTERVENTIONAL | false | ZevraDenmark | A multicenter, non-randomized, open label trial, to assess long term safety and efficacy of Arimoclomol in subjects with Amyotrophic Lateral Sclerosis (ALS) who have completed the ORARIALS-01 trial. | [
{
"type": "DRUG",
"name": "Arimoclomol"
}
] | 2019-09-19 | https://clinicaltrials.gov/study/NCT03836716 | [
"heat_shock_response"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center (SJHMC) - Barrow Neurological Institute (BNI) - The Gregory W. Fulton ALS and Neuromuscular Disease Center",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
... | null | {
"compound": "Arimoclomol",
"targeting_mechanism": "Heat shock response modulation to enhance TDP-43 clearance.",
"targeting_mechanism_pmid": "26936937",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04931862 | Study of WVE-004 in Patients With C9orf72-associated Amyotrophic Lateral Sclerosis (ALS) or Frontotemporal Dementia (FTD) | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Wave Life Sciences USA, Inc. | This is a Phase 1b/2a multicenter, randomized, double-blind, placebo-controlled study to evaluate the safety, tolerability, PK, and PD of intrathecal (IT) WVE-004 in adult patients with C9orf72-associated ALS or FTD. To participate in the study, patients must have a documented mutation (GGGGCC \[G4C2\] repeat expansion... | [
{
"type": "DRUG",
"name": "WVE-004"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2021-06-28 | https://clinicaltrials.gov/study/NCT04931862 | [
"C9orf72"
] | [
{
"facility": "Macquarie University",
"city": "North Ryde",
"state": "New South Wales",
"country": "Australia",
"status": "",
"lat": -33.79677,
"lon": 151.12436
},
{
"facility": "The Wesley Hospital",
"city": "Brisbane",
"state": "Queensland",
"country": "Australia",
... | null | {
"compound": "WVE-004",
"targeting_mechanism": "Antisense oligonucleotide targeting C9orf72 GGGGCC repeat expansion to reduce pathogenic dipeptide repeat protein production.",
"targeting_mechanism_pmid": "27768896",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed"... | ||
NCT04055623 | T-regulatory Cells in ALS | PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | The Methodist Hospital Research Institute | This study is a randomized, placebo-controlled, phase 2a trial to study the biological activity, safety, and tolerability of regulatory T Lymphocytes (Tregs) taken and expanded outside of the body and returned back to the same person whose Treg were removed, given back by IV (intravenously) and in combination with low-... | [
{
"type": "BIOLOGICAL",
"name": "Monthly autologous Treg cells infusions + 3 times per week Interleukin-2 injections"
},
{
"type": "OTHER",
"name": "Monthly placebo infusions + 3 times per week placebo injections"
},
{
"type": "BIOLOGICAL",
"name": "Monthly autologous Treg cells infu... | 2019-08-07 | https://clinicaltrials.gov/study/NCT04055623 | [
"neuroinflammation",
"IL2"
] | [
{
"facility": "Massachusetts General Hospital Neurological Clinical Research Institute",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
},
{
"facility": "Houston Methodist Hospital",
"city": "Houston",
... | null | {
"compound": "autologous regulatory T cells (Tregs) with low-dose interleukin-2",
"targeting_mechanism": "Expansion and reinfusion of regulatory T cells combined with low-dose IL-2 to enhance Treg-mediated suppression of neuroinflammation in ALS.",
"targeting_mechanism_pmid": "32651161",
"animal_results": "unk... | ||
NCT05974579 | Safety and Dosimetry of a New Radiotracer to Detect Misfolded SOD1 Associated With Amyotrophic Lateral Sclerosis | PHASE1 | COMPLETED | INTERVENTIONAL | false | Université de Sherbrooke | Amyotrophic lateral sclerosis (ALS), also known as Lou Gehrig's Disease, is a rare neurodegenerative disease resulting in loss, primarily, of the motor neurons in the motor cortex, brainstem and spinal cord. It currently affects 3 of every 100,000 people in the US.
Currently, there is no diagnostic tool for ALS, resul... | [
{
"type": "DRUG",
"name": "89Zr-DFO-AP-101"
}
] | 2023-11-23 | https://clinicaltrials.gov/study/NCT05974579 | [
"SOD1"
] | [
{
"facility": "CIUSSS de l'Estrie-CHUS Hospital",
"city": "Sherbrooke",
"state": "Quebec",
"country": "Canada",
"status": "",
"lat": 45.40008,
"lon": -71.89908
}
] | null | {
"compound": "89Zr-DFO-AP-101",
"targeting_mechanism": "Radiotracer designed to detect and image misfolded SOD1 protein associated with ALS for diagnostic and disease monitoring purposes.",
"targeting_mechanism_pmid": "29751510",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "n... | ||
NCT03272503 | A Clinical Trial of Pimozide in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | UNKNOWN | INTERVENTIONAL | false | University of Calgary | This study will look at whether Pimozide may help to slow the progression of Amyotrophic Lateral Sclerosis.
100 people from several Canadian centres with ALS who have provided their consent will be randomly assigned into one of 2 groups. The first group will receive a dose of up to 2mg of Pimozide per day and the seco... | [
{
"type": "DRUG",
"name": "Pimozide 2mg/day (current) or 4 mg/day (study initiation)"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2017-10-27 | https://clinicaltrials.gov/study/NCT03272503 | [
"dopamine_receptor"
] | [
{
"facility": "Dr. Lawrence Korngut -South Health Campus",
"city": "Calgary",
"state": "Alberta",
"country": "Canada",
"status": "RECRUITING",
"lat": 51.05011,
"lon": -114.08529
},
{
"facility": "Dr. Wendy Johnston - University of Alberta",
"city": "Edmonton",
"state": "A... | 403-210-7006 | Pimozide2@ucalgary.ca | null | {
"compound": "Pimozide",
"targeting_mechanism": "Neuroleptic that stabilizes neuromuscular transmission by modulating calcium channel activity and preventing motor neuron dysfunction.",
"targeting_mechanism_pmid": "29202456",
"animal_results": "Pimozide stabilized neuromuscular transmission in multiple disease... |
NCT01995903 | Developing a Discrimination Model to Diagnose ALS | NA | COMPLETED | INTERVENTIONAL | false | University of Michigan | To combine several brain imaging techniques to develop a new diagnostic test to help with earlier diagnosis of amyotrophic lateral sclerosis. | [
{
"type": "DIAGNOSTIC_TEST",
"name": "MRI(magnetic resonance imaging)"
}
] | 2012-04 | https://clinicaltrials.gov/study/NCT01995903 | [] | [
{
"facility": "University of Michigan Hospital",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04719403 | Determining Feasibility and Acceptability of Sharing Video Recordings With Patients With ALS and Caregivers | NA | COMPLETED | INTERVENTIONAL | false | Dartmouth-Hitchcock Medical Center | Our objective in the proposed project is to: (a) operationalize and determine the feasibility and acceptability of a trial where clinic multi-disciplinary clinic (MDC) visits are audio/video recorded and shared with patients with ALS and their caregivers; (b) gather preliminary data examining the impact of routinely ad... | [
{
"type": "OTHER",
"name": "HealthPAL"
}
] | 2021-05-12 | https://clinicaltrials.gov/study/NCT04719403 | [] | [
{
"facility": "Dartmouth-Hitchcock Medical Center",
"city": "Lebanon",
"state": "New Hampshire",
"country": "United States",
"status": "",
"lat": 43.64229,
"lon": -72.25176
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04288856 | Study to Assess the Safety, Tolerability, Pharmacokinetics, and Effect on Disease Progression of BIIB078 Administered to Previously Treated Adults C9ORF72-Associated Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | TERMINATED | INTERVENTIONAL | false | Biogen | The primary objective is to evaluate the long-term safety and tolerability of BIIB078 in participants with chromosome 9 open reading frame 72-amyotrophic lateral sclerosis (C9ORF72-ALS).
The secondary objective is to evaluate the pharmacokinectic (PK) of BIIB078 in participants with C9ORF72-ALS. | [
{
"type": "DRUG",
"name": "BIIB078"
}
] | 2020-04-28 | https://clinicaltrials.gov/study/NCT04288856 | [
"C9orf72"
] | [
{
"facility": "Research Site",
"city": "La Jolla",
"state": "California",
"country": "United States",
"status": "",
"lat": 32.84727,
"lon": -117.2742
},
{
"facility": "Research Site",
"city": "Los Angeles",
"state": "California",
"country": "United States",
"statu... | null | {
"compound": "BIIB078",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07539662 | Unrelated Umbilical Cord Blood Transplantation for the Treatment of Amyotrophic Lateral Sclerosis (ALS) | NA | ENROLLING_BY_INVITATION | INTERVENTIONAL | false | Institute of Hematology & Blood Diseases Hospital, China | Amyotrophic Lateral Sclerosis (ALS) is a rapidly progressive and fatal neurodegenerative disorder. Its global prevalence is approximately 0.73-1.89 per 100,000 individuals. In China, there are about 200,000 ALS patients, with approximately 25,000 new cases diagnosed annually. Microglia, the resident immune cells of the... | [
{
"type": "PROCEDURE",
"name": "Mobilization Regimen"
},
{
"type": "PROCEDURE",
"name": "Conditioning Regimen"
},
{
"type": "PROCEDURE",
"name": "GVHD Prophylaxis"
},
{
"type": "PROCEDURE",
"name": "umbilical cord blood"
},
{
"type": "PROCEDURE",
"name": "Resc... | 2025-12-29 | https://clinicaltrials.gov/study/NCT07539662 | [
"neuroinflammation"
] | [
{
"facility": "Institute of Hematology & Blood Diseases Hospital",
"city": "Tianjin",
"state": "",
"country": "China",
"status": "",
"lat": 39.14222,
"lon": 117.17667
}
] | null | {
"compound": "umbilical cord blood",
"targeting_mechanism": "modulation of microglia from pro-inflammatory (M1) state to reduce neuroinflammation in the central nervous system",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"r... | ||
NCT07571486 | Therapeutic Approach of Repeated Transient Blood-brain Barrier Opening in Amyotrophic Lateral Sclerosis. | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | This is proof-of-concept, single-arm, single-center study to assess the safety and explore the efficacy of repeated US transient disruptions of the blood-brain barrier (BBB) in Amyotrophic Lateral Sclerosis (ALS).
Phase 1:
The primary objective is to assess the safety of ultrasound induced BBB opening in the upper mo... | [
{
"type": "DEVICE",
"name": "SonoCloud-4 (SC4) device"
}
] | 2026-07-15 | https://clinicaltrials.gov/study/NCT07571486 | [
"blood_brain_barrier_permeability"
] | [
{
"facility": "Hôpital Pitié-Salpêtrière",
"city": "Paris",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 48.85341,
"lon": 2.3488
}
] | 1 42 16 24 72 | gaelle.bruneteau@aphp.fr | null | {
"compound": "SonoCloud-4 (SC4) device",
"targeting_mechanism": "ultrasound-induced transient disruption of the blood-brain barrier to enable therapeutic delivery to motor neurons",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
... |
NCT00005766 | Clinical Trial of Creatine in Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | National Center for Research Resources (NCRR) | The objective of this study is to determine whether creatine slows disease progression in subjects with amyotrophic lateral sclerosis (ALS). ALS is a progressive uniformly lethal neurodegenerative disorder for which there is no known cure. Recent genetic and biochemical studies implicate free radical toxicity, glutamat... | [
{
"type": "DRUG",
"name": "Creatinine"
}
] | https://clinicaltrials.gov/study/NCT00005766 | [
"oxidative_stress",
"mitochondrial_dysfunction",
"glutamate_excitotoxicity"
] | [
{
"facility": "University of Vermont",
"city": "Burlington",
"state": "Vermont",
"country": "United States",
"status": "",
"lat": 44.47588,
"lon": -73.21207
}
] | null | {
"compound": "Creatinine",
"targeting_mechanism": "mitochondrial support and reduction of free radical toxicity, glutamate excitotoxicity, and mitochondrial dysfunction",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from... | |||
NCT03519880 | A Pilot Study of the Utility of 3D Printed Masks for ALS Subjects | NA | TERMINATED | INTERVENTIONAL | false | University of Michigan | Non-invasive ventilation (NIV) is an important therapy for patients with a number of neurological diseases. Specifically, NIV has been shown to be an effective treatment for people with amyotrophic lateral sclerosis (ALS, also known as Lou Gehrig's disease), which is a fatal, non-curable, progressive disease of the mot... | [
{
"type": "DEVICE",
"name": "Custom Mask Interface"
}
] | 2017-03-14 | https://clinicaltrials.gov/study/NCT03519880 | [] | [
{
"facility": "Michigan Medicine",
"city": "Ann Arbor",
"state": "Michigan",
"country": "United States",
"status": "",
"lat": 42.27756,
"lon": -83.74088
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06834269 | Transcranial Static Magnetic Stimulation (tSMS) and Potential Theranostic Biomarkers in Amyotrophic Lateral Sclerosis. | NA | RECRUITING | INTERVENTIONAL | false | Campus Bio-Medico University | The objective of the present study is to assess the efficacy of tSMS in ALS patients. This will be achieved by monitoring:
* levels of NF-L and other potential innovative biomarkers,
* clinical progression, trough ALSFRS-R. After at least three-month follow-up, participants will be recruited to undergo biemispheric tS... | [
{
"type": "DEVICE",
"name": "Transcranial magnetic stimulation (tSMS)"
}
] | 2024-12-02 | https://clinicaltrials.gov/study/NCT06834269 | [
"motor_cortex_excitability"
] | [
{
"facility": "Fondazione Policlinico Campus Bio-Medico",
"city": "Roma",
"state": "RM",
"country": "Italy",
"status": "RECRUITING",
"lat": 44.99364,
"lon": 11.10642
}
] | 06 22541 1220 | v.dilazzaro@policlinicocampus.it | null | {
"compound": "Transcranial static magnetic stimulation (tSMS)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT01786603 | Rasagiline in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Richard Barohn, MD | ALS is a disorder that weakens motor strength and lung function. Rapid loss of motor neurons in the brain and spinal cord of ALS patients causes the symptoms of increasing weakness and loss of muscle function. Motor neurons are responsible for sending signals to muscles in our bodies to trigger movement. While there ar... | [
{
"type": "DRUG",
"name": "Rasagiline"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2013-11-21 | https://clinicaltrials.gov/study/NCT01786603 | [
"Monoamine oxidase"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California - Irvine",
"city": "Irvine",
"state": "California",
"country... | null | {
"compound": "Rasagiline",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04297683 | HEALEY ALS Platform Trial - Master Protocol | PHASE2, PHASE3 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Merit E. Cudkowicz, MD | The HEALEY ALS Platform Trial is a perpetual multi-center, multi-regimen clinical trial evaluating the safety and efficacy of investigational products for the treatment of ALS. | [
{
"type": "DRUG",
"name": "Zilucoplan"
},
{
"type": "DRUG",
"name": "Verdiperstat"
},
{
"type": "DRUG",
"name": "CNM-Au8"
},
{
"type": "DRUG",
"name": "Pridopidine"
},
{
"type": "DRUG",
"name": "SLS-005 Trehalose"
},
{
"type": "DRUG",
"name": "ABBV... | 2020-06-14 | https://clinicaltrials.gov/study/NCT04297683 | [
"Complement C5",
"Myeloperoxidase",
"Huntingtin",
"Neurofilament light chain",
"immunomodulation"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Mayo Clinic Scottsdale",
"city": "Scottsdale",
"state": "Arizona",
"country": "United S... | null | {
"compound": "Zilucoplan, Verdiperstat, CNM-Au8, Pridopidine, SLS-005 Trehalose, ABBV-CLS-7262, DNL343, NUZ-001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07294144 | Tofersen in Non-SOD1 ALS | PHASE2 | RECRUITING | INTERVENTIONAL | false | Washington University School of Medicine | The goal of this clinical trial is to evaluate whether tofersen is safe and effective in adults with non-SOD1 ALS. Tofersen is currently approved by the U.S. Food and Drug Administration to treat SOD1-ALS. The main questions it aims to answer are:
* Does tofersen lower the levels of neurofilament light chain (NfL) in ... | [
{
"type": "DRUG",
"name": "Tofersen"
}
] | 2025-12-29 | https://clinicaltrials.gov/study/NCT07294144 | [
"Neurofilament light chain"
] | [
{
"facility": "Emory University",
"city": "Atlanta",
"state": "Georgia",
"country": "United States",
"status": "RECRUITING",
"lat": 33.749,
"lon": -84.38798
},
{
"facility": "Massachusetts General Hospital",
"city": "Boston",
"state": "Massachusetts",
"country": "Unit... | null | {
"compound": "Tofersen",
"targeting_mechanism": "Antisense oligonucleotide that reduces SOD1 messenger RNA and protein expression.",
"targeting_mechanism_pmid": "37975798",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03067857 | Autologous Bone Marrow-Derived Stem Cell Therapy for Motor Neuron Disease | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | Stem Cells Arabia | Herein, the investigators study the safety and efficacy of transplanting purified autologous bone marrow-derived stem cells transplanted via the intrathecal route by interventional radiology and the intravenous route. | [
{
"type": "BIOLOGICAL",
"name": "Stem Cells"
}
] | 2016-09 | https://clinicaltrials.gov/study/NCT03067857 | [
"neuroprotection"
] | [] | null | {
"compound": "Autologous bone marrow-derived stem cells",
"targeting_mechanism": "Stem cells differentiate into support cells (astrocytes, oligodendrocytes, microglia) that produce growth factors and anti-inflammatory cytokines, provide nutrients, and buffer excessive glutamate to benefit degenerating motor neuron... | ||
NCT06396260 | Structural and Functional Networks in ALS: An Insight Into Pseudobulbar Affect | NA | RECRUITING | INTERVENTIONAL | false | Aalborg University Hospital | The investigators aim to elucidate characteristics of structural and functional brain connectivity in patients with amyotrophic lateral sclerosis (ALS) and pseudobulbar affect (PBA) using diffusion kurtosis imaging (DKI) and magnetoencephalography (MEG). | [
{
"type": "OTHER",
"name": "Diffusion Kurtosis Imaging (DKI)"
},
{
"type": "OTHER",
"name": "Resting State Magnetoencephalography"
}
] | 2024-05-26 | https://clinicaltrials.gov/study/NCT06396260 | [] | [
{
"facility": "Aalborg University hospital",
"city": "Aalborg",
"state": "Northern Jutland",
"country": "Denmark",
"status": "RECRUITING",
"lat": 57.048,
"lon": 9.9187
}
] | +4597660000 | c.steenkjaer@rn.dk | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03892382 | Repetitive Transcranial Magnetic Stimulation as Therapy for Apathy in Amyotrophic Lateral Sclerosis | NA | WITHDRAWN | INTERVENTIONAL | false | Jagiellonian University | Amyotrophic lateral sclerosis (ALS) is a neurodegenerative disease characterized by progressive loss of central and peripheral motor neurons. ALS leads to death usually within 3 to 5 years from the onset of the symptoms. Available treatment can prolong the disease duration but cannot modify the disease course. Apathy i... | [
{
"type": "DEVICE",
"name": "rTMS"
}
] | 2019-11-15 | https://clinicaltrials.gov/study/NCT03892382 | [
"motor_cortex_excitability"
] | [
{
"facility": "Jagiellonian University Medical College, Department of Neurology",
"city": "Krakow",
"state": "",
"country": "Poland",
"status": "",
"lat": 50.06143,
"lon": 19.93658
}
] | null | {
"compound": "rTMS (repetitive transcranial magnetic stimulation)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00982150 | Extension Study of Talampanel for Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | Teva Branded Pharmaceutical Products R&D, Inc. | This will be an open label treatment extension phase in patients with ALS who have previously participated in the double blind, placebo-controlled ALS-TAL-201 study. This study will make talampanel treatment available to all subjects who completed the double blind placebo-controlled phase of ALS-TAL-201 study and where... | [
{
"type": "DRUG",
"name": "Talampanel"
}
] | 2009-09 | https://clinicaltrials.gov/study/NCT00982150 | [
"AMPA receptor"
] | [] | null | {
"compound": "Talampanel",
"targeting_mechanism": "AMPA receptor antagonist that blocks glutamate signaling through AMPA receptors to reduce excitotoxic motor neuron injury.",
"targeting_mechanism_pmid": "27350567",
"animal_results": "AMPA receptor antagonist perampanel robustly rescues ALS pathology in sporad... | ||
NCT06711510 | Predict to Prevent PGRN Disease | NA | WITHDRAWN | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | Progranulin (GRN or PGRN) mutations are among the most common genetic causes of frontotemporal lobar degeneration (FTLD). With the advent of gene-specific therapeutic interventions, an accurate knowledge of the presymptomatic phase of the disease is of utmost importance. Increases of plasma neurofilament light chain (N... | [
{
"type": "OTHER",
"name": "Clinical, behavioral and cognitive evaluation"
},
{
"type": "OTHER",
"name": "blood sampling"
},
{
"type": "OTHER",
"name": "brain MRI"
},
{
"type": "OTHER",
"name": "olfactory swab sampling with nasal brush"
},
{
"type": "OTHER",
"... | 2025-01 | https://clinicaltrials.gov/study/NCT06711510 | [
"GRN"
] | [] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03954600 | A Study to Assess the Safety, Tolerability and PK of NPT520-34 in Healthy Subjects | PHASE1 | COMPLETED | INTERVENTIONAL | false | Neuropore Therapies Inc. | To evaluate the PK, safety and tolerability of orally administered NPT520-34 in healthy subjects at single and multiple doses that may be therapeutically relevant. | [
{
"type": "DRUG",
"name": "NPT520-34 (125 mg)"
},
{
"type": "DRUG",
"name": "Placebos (125 mg)"
}
] | 2019-05-05 | https://clinicaltrials.gov/study/NCT03954600 | [
"TAU",
"neuroinflammation"
] | [
{
"facility": "Celerion, Inc",
"city": "Tempe",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.41477,
"lon": -111.90931
}
] | null | {
"compound": "NPT520-34",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03411863 | Cervical Electrical Stimulation for ALS | NA | COMPLETED | INTERVENTIONAL | false | VA Office of Research and Development | Veterans are at higher risk than non-Veterans of falling ill with amyotrophic lateral sclerosis (ALS). ALS causes degeneration of motor neurons in both the brain and the spinal cord. Evidence from studies in people with spinal cord injury suggests that activating spared nerve circuits with electromagnetic stimulation i... | [
{
"type": "DEVICE",
"name": "CES at rest"
},
{
"type": "DEVICE",
"name": "CES plus active hand or wrist movements"
}
] | 2018-01-04 | https://clinicaltrials.gov/study/NCT03411863 | [
"motor_neuron_circuits"
] | [
{
"facility": "James J. Peters VA Medical Center, Bronx, NY",
"city": "The Bronx",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.84985,
"lon": -73.86641
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT07401121 | Safety and Tolerability Study of CTx1000 In Participants With Amyotrophic Lateral Sclerosis | PHASE1 | RECRUITING | INTERVENTIONAL | false | Celosia Therapeutics Pty Ltd | This clinical study is in participants with Amyotrophic Lateral Sclerosis and is designed to evaluate the safety and tolerability of the gene therapy CTx1000. | [
{
"type": "DRUG",
"name": "AAV9 Gene therapy"
}
] | 2026-01-12 | https://clinicaltrials.gov/study/NCT07401121 | [
"SMN1"
] | [
{
"facility": "Macquarie University Hospital",
"city": "Sydney",
"state": "New South Wales",
"country": "Australia",
"status": "RECRUITING",
"lat": -33.86785,
"lon": 151.20732
}
] | null | {
"compound": "CTx1000",
"targeting_mechanism": "AAV9-delivered gene therapy targeting motor neuron degeneration in ALS.",
"targeting_mechanism_pmid": "33839324",
"animal_results": "In AAV9-amiRSOD1 treatment, a 50% increase in median survival and preservation of motor function were achieved in SOD1G93A transge... | ||
NCT03272802 | Treatment Effect of Edaravone in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | UNKNOWN | INTERVENTIONAL | false | Isfahan University of Medical Sciences | Amyotrophic Lateral Sclerosis (ALS) is a neurodegenerative disease that causes the death of 30,000 affected individual every year. Complex nature and unknown pathogenesis of this disease are 2 major reasons for failure of therapeutic interventions. Edaravone is a free radical scavenger that slows down functional declin... | [
{
"type": "DRUG",
"name": "Edaravone"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2017-03-16 | https://clinicaltrials.gov/study/NCT03272802 | [
"oxidative_stress"
] | [
{
"facility": "EMG Department, Alzahra Hospital",
"city": "Isfahan",
"state": "",
"country": "Iran",
"status": "",
"lat": 32.65246,
"lon": 51.67462
}
] | null | {
"compound": "Edaravone",
"targeting_mechanism": "Free radical scavenger that quenches hydroxyl radicals and inhibits lipid peroxidation.",
"targeting_mechanism_pmid": "38474192",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "acute cerebral infarction",
"repurposed_from_pmid... | ||
NCT01565395 | Incobotulinum Toxin A for Sialorrhea in Parkinson's Disease (PD)/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | WITHDRAWN | INTERVENTIONAL | false | Beth Israel Deaconess Medical Center | The purpose of this study is to evaluate the safety and efficacy of Incobotulinum Toxin A (Xeomin®) injections into the parotid and submandibular glands in patients with Parkinson's Disease/Parkinsonism and Amyotrophic Lateral Sclerosis (ALS) with troublesome sialorrhea. | [
{
"type": "DRUG",
"name": "Incobotulinum Toxin A"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2012-03 | https://clinicaltrials.gov/study/NCT01565395 | [
"acetylcholine"
] | [
{
"facility": "Beth Israel Deaconess Medical Center",
"city": "Boston",
"state": "Massachusetts",
"country": "United States",
"status": "",
"lat": 42.35843,
"lon": -71.05977
}
] | null | {
"compound": "Incobotulinum Toxin A",
"targeting_mechanism": "Botulinum toxin that inhibits acetylcholine release at the neuromuscular junction to reduce salivary gland secretion.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
... | ||
NCT06391645 | Nerve Growth Factor Encapsulated With 2-methacryloyloxyethyl Phosphorylcholine Nanocapsules in the Treatment of Amyotrophic Lateral Sclerosis | PHASE2, PHASE3 | NOT_YET_RECRUITING | INTERVENTIONAL | false | Beijing Tiantan Hospital | Amyotrophic lateral sclerosis (ALS) is one of the most lethal neurodegenerative diseases, with most patients dying from respiratory failure 3-5 years after the onset. The purpose of this study is to explore the efficacy and safety of nerve growth factor (NGF) encapsulated with 2-methacryloyloxyethyl phosphorylcholine (... | [
{
"type": "DRUG",
"name": "Nerve Growth Factor"
}
] | 2024-05 | https://clinicaltrials.gov/study/NCT06391645 | [
"NGF"
] | [] | 13521588395 | liuxinru0826@163.com | null | {
"compound": "Nerve Growth Factor encapsulated with 2-methacryloyloxyethyl phosphorylcholine nanocapsules",
"targeting_mechanism": "Nerve growth factor (NGF) promotes neuronal survival and growth to support motor neuron function.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_... |
NCT05632757 | Anticipated Patient and Caregiver Burden | NA | RECRUITING | INTERVENTIONAL | false | Assistance Publique Hopitaux De Marseille | Amyotrophic lateral sclerosis (ALS) is a degenerative neurological disease that causes progressive motor disability and is life threatening within a few years. The severity of the disease, the progressive loss of autonomy that leads to dependence on family and caregivers, and the lack of effective treatment sometimes l... | [
{
"type": "BEHAVIORAL",
"name": "Psychological assessments"
}
] | 2023-06-22 | https://clinicaltrials.gov/study/NCT05632757 | [] | [
{
"facility": "Service Maladies neuromusculaires et SLA",
"city": "Marseille",
"state": "",
"country": "France",
"status": "RECRUITING",
"lat": 43.29695,
"lon": 5.38107
}
] | 0491386578 | annie.verschueren@ap-hm.fr | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT00035815 | Insulin-like Growth Factor-1 in Amyotrophic Lateral Sclerosis (ALS) Trial | PHASE3 | COMPLETED | INTERVENTIONAL | false | Mayo Clinic | The purpose of this multicenter study is to determine if insulin-like growth factor-1 (IGF-I) slows the progressive weakness in amyotrophic lateral sclerosis (ALS) patients. Study participants will be followed for 2 years once enrolled. They will receive either placebo or the active IGF-I. Examinations will take place ... | [
{
"type": "DRUG",
"name": "Insulin like growth factor, type 1"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2003-06 | https://clinicaltrials.gov/study/NCT00035815 | [
"IGF1"
] | [
{
"facility": "Mayo Clinic in Scottsdale",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California",
"cou... | null | {
"compound": "Insulin-like growth factor-1",
"targeting_mechanism": "Insulin-like growth factor-1 (IGF-I) promotes motor neuron survival and slows progressive weakness through growth factor signaling.",
"targeting_mechanism_pmid": "",
"animal_results": "Intramuscular delivery of scAAV9-hIGF1 prolonged survival... | ||
NCT04089696 | Validation of the "ExSpiron©" in Patients With ALS | NA | UNKNOWN | INTERVENTIONAL | false | University Medical Center Groningen | Non-invasive ventilation (NIV) in patients diagnosed with amyotrophic lateral sclerosis (ALS) is nowadays common practice to provide comfort at the end stage of the disease. As complaints vary there is the need of a non-invasive device to measure respiratory volume to objectify complaints.
The ExSpiron© is a device fo... | [
{
"type": "DEVICE",
"name": "ExSprion"
}
] | 2025-09 | https://clinicaltrials.gov/study/NCT04089696 | [] | [] | +31 50 3613200 | p.j.wijsktra@umcg.nl | null | {
"compound": "ExSpiron",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT07322003 | Pridopidine Phase 3 Study to Evaluate Efficacy and Safety in ALS | PHASE3 | RECRUITING | INTERVENTIONAL | false | Prilenia | The goal of this clinical trial is to learn if the drug pridopidine works to treat amyotrophic lateral sclerosis in adults. It will also help to learn about the safety of pridopidine. The main question it aims to answer is:
Does pridopidine slow disease progression of ALS?
Researchers will compare pridopidine to a pl... | [
{
"type": "DRUG",
"name": "Pridopidine"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2026-02-01 | https://clinicaltrials.gov/study/NCT07322003 | [
"Sigma-1 receptor"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "RECRUITING",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "California Pacific Medical Center",
"city": "San Francisco",
"state": "California... | 857-574-5755 | MedInfo@prilenia.com | null | {
"compound": "Pridopidine",
"targeting_mechanism": "Pridopidine is a sigma-1/2 receptor modulator for the treatment of neurodegenerative disorders.",
"targeting_mechanism_pmid": "37166702",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06849115 | Effects of L-Carnitine in Amyotrophic Lateral Sclerosis Patients With CHCHD10 Mutations | PHASE4 | COMPLETED | INTERVENTIONAL | false | ChaodongWang | The study was designed as a single-center, open-label, single-arm pilot study to estimate the safety and efficacy L-carnitine in ALS patients with CHCHD10 mutations. | [
{
"type": "DRUG",
"name": "L-Carnitine Injection，1000mg once daily"
}
] | 2024-07-18 | https://clinicaltrials.gov/study/NCT06849115 | [
"CHCHD10",
"mitochondrial_dysfunction"
] | [
{
"facility": "Xuanwu Hospital, Capital Medical University",
"city": "Beijing",
"state": "China",
"country": "China",
"status": "",
"lat": 39.9075,
"lon": 116.39723
}
] | null | {
"compound": "L-Carnitine",
"targeting_mechanism": "L-Carnitine improves mitochondrial function and energy production in the context of CHCHD10-associated mitochondrial dysfunction.",
"targeting_mechanism_pmid": "38002924",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown... | ||
NCT06100276 | Safety, Tolerability, and Exploratory Efficacy Study of Intrathecally Administered Gene Therapy AMT-162 in Adult Participants With SOD1 Amyotrophic Lateral Sclerosis (SOD1-ALS) | PHASE1, PHASE2 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | UniQure Biopharma B.V. | This is the study of AMT-162 in Participants with SOD1-ALS and is designed to evaluate the safety, tolerability, and exploratory efficacy of intrathecally administered gene therapy AMT-162. AMT-162-001 is a Phase 1/2, multi-center, single ascending dose study. | [
{
"type": "DRUG",
"name": "AMT-162"
}
] | 2024-08-01 | https://clinicaltrials.gov/study/NCT06100276 | [
"SOD1"
] | [
{
"facility": "Barrow Neurological Institute",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California Irvine",
"city": "Irvine",
"state": "California",
"country": "... | null | {
"compound": "AMT-162",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT01906658 | A Study to Explore the Safety and Tolerability of Acthar in Patients With Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Mallinckrodt | This 8-week randomized, open-label evaluation will examine the acute safety and tolerability of 4 different dosing regimens of Acthar to inform dose selection for future studies of Acthar in patients with Amyotrophic Lateral Sclerosis (ALS). The study will also investigate the mean rate of change in the ALSFRS-R total ... | [
{
"type": "DRUG",
"name": "Repository corticotropin injection"
}
] | 2013-07 | https://clinicaltrials.gov/study/NCT01906658 | [
"neuroinflammation"
] | [
{
"facility": "Questcor Investigational Site",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "Questcor Investigational Site",
"city": "Phoenix",
"state": "Arizona",
"country": "Un... | null | {
"compound": "Repository corticotropin injection (Acthar)",
"targeting_mechanism": "Acthar modulates neuroinflammation to reduce the chronic inflammatory response that contributes to motor neuron degeneration.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "CSF1R blockade slows ALS progression by ... | ||
NCT03506425 | A Pilot Trial of Triheptanoin for People With Amyotrophic Lateral Sclerosis (PALS) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Richard Bedlack, M.D., Ph.D. | The causes of ALS are largely unknown. However, mitochondrial dysfunction, resulting in impaired energy production, oxidative stress and apoptosis, may play a key role in ALS progression. Triheptanoin can improve mitochondrial function and energy production and therefore has potential for slowing ALS progression. Indee... | [
{
"type": "DRUG",
"name": "Triheptanoin"
}
] | 2018-06-21 | https://clinicaltrials.gov/study/NCT03506425 | [
"mitochondrial_dysfunction",
"oxidative_stress"
] | [
{
"facility": "Duke University",
"city": "Durham",
"state": "North Carolina",
"country": "United States",
"status": "",
"lat": 35.99403,
"lon": -78.89862
}
] | null | {
"compound": "Triheptanoin",
"targeting_mechanism": "Triheptanoin improves mitochondrial function and energy production to reduce oxidative stress and motor neuron loss.",
"targeting_mechanism_pmid": "38002924",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurp... | ||
NCT03948178 | Effects of Oral Levosimendan on Respiratory Function in Patients With Amyotrophic Lateral Sclerosis (ALS): Open-Label Extension | PHASE3 | TERMINATED | INTERVENTIONAL | false | Orion Corporation, Orion Pharma | This study provides an opportunity for subjects in the REFALS (3119002; NCT03505021) study to continue treatment with oral levosimendan. The study will also provide more information about long-term safety and effectiveness of oral levosimendan in patients with ALS.
This is an open-label study, so that all eligible sub... | [
{
"type": "DRUG",
"name": "Levosimendan"
}
] | 2019-06-26 | https://clinicaltrials.gov/study/NCT03948178 | [
"cardiac_contractility"
] | [
{
"facility": "Neuromuscular research Centre and Neuromuscular Clinic of Arizona",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "University of California San Diego",
"city": "La Jolla",
... | null | {
"compound": "Levosimendag",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02464748 | Telehealth in Motor Neurone Disease | NA | COMPLETED | INTERVENTIONAL | false | Sheffield Teaching Hospitals NHS Foundation Trust | Motor neurone disease (MND) is a rare but debilitating neurological condition that causes paralysis of the body's muscles leading to severe disability and eventually death. Patients often struggle to travel the long distances to specialist clinics to receive the care they require whilst this expert care is often unavai... | [
{
"type": "OTHER",
"name": "TiM telehealth arm"
}
] | 2014-09 | https://clinicaltrials.gov/study/NCT02464748 | [] | [
{
"facility": "Sheffield Institute for Translational Neurosciences",
"city": "Sheffield",
"state": "",
"country": "United Kingdom",
"status": "",
"lat": 53.38297,
"lon": -1.4659
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT03160898 | A Study to Evaluate Efficacy, Safety and Tolerability of CK-2127107 in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Cytokinetics | The purpose of this study was to assess the effect of CK-2127107 (hereafter referred to as reldesemtiv) versus placebo on respiratory function and other measures of skeletal muscle function in patients with ALS. | [
{
"type": "DRUG",
"name": "Reldesemtiv"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2017-07-24 | https://clinicaltrials.gov/study/NCT03160898 | [
"skeletal_muscle_function"
] | [
{
"facility": "St. Joseph's Hospital and Medical Center - Barrow Neurological Clinics",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai Medical Center",
"city": "Los Angeles",
... | null | {
"compound": "Reldesemtiv (CK-2127107)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03693781 | Colchicine for Amyotrophic Lateral Sclerosis | PHASE2 | COMPLETED | INTERVENTIONAL | false | Azienda Ospedaliero-Universitaria di Modena | The study evaluates the effects of two different Colchicine doses (0.01mg/kg/day or 0.005 mg/kg/day) compared to placebo in Amyotrophic Lateral Sclerosis (ALS) patients. Disease progression as defined by changes in ALSFRS-r is the primary outcome measure. Other measures of clinical progression and survival, together wi... | [
{
"type": "DRUG",
"name": "Colchicine 1 MG Oral Tablet"
},
{
"type": "DRUG",
"name": "Colchicine 1 MG Oral Tablet"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2019-04-10 | https://clinicaltrials.gov/study/NCT03693781 | [
"neuroinflammation"
] | [
{
"facility": "Centro Sla, University of Bari",
"city": "Bari",
"state": "",
"country": "Italy",
"status": "",
"lat": 41.12066,
"lon": 16.86982
},
{
"facility": "Centro Sla, Istituto Auxologico Italiano, University of Milano, Milano",
"city": "Milan",
"state": "",
"co... | null | {
"compound": "Colchicine",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06513546 | A Study to Evaluate the Safety, Efficacy, and Pharmacodynamics of PLL001 in ALS Patients | PHASE1, PHASE2 | NOT_YET_RECRUITING | INTERVENTIONAL | false | PLL TX AUSTRALIA PTY LTD | FIH, Phase 1/2, multi-centre, randomised, double-blind, placebo controlled study with an optional open-label dosing extension to assess the safety, tolerability, efficacy, and Pharmacodynamics (PD) of single or multiple (up to 48 weeks QD) subcutaneous (SC) doses of PLL001 compared to placebo in subjects diagnosed with... | [
{
"type": "DRUG",
"name": "PLL001 or placebo daily subcutaneous injections"
}
] | 2026-04-08 | https://clinicaltrials.gov/study/NCT06513546 | [
"neuroinflammation"
] | [] | +61 (0)429 300 705 | Tina.Soulis@alithialifesciences.com | null | {
"compound": "PLL001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT03482050 | A Study to Evaluate Transplantation of Astrocytes Derived From Human Embryonic Stem Cells, in Patients With Amyotrophic Lateral Sclerosis (ALS) | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Kadimastem | This is a study of transplantation of Astrocytes derived from human embryonic stem cells, in patients with Amyotrophic Lateral Sclerosis (ALS).
There will be no change in the routine ALS treatment of the patients enrolled into the study. Treatment will be administered in addition to the appropriate standard of care tr... | [
{
"type": "BIOLOGICAL",
"name": "AstroRx"
}
] | 2018-04-12 | https://clinicaltrials.gov/study/NCT03482050 | [
"neurodegeneration"
] | [
{
"facility": "Hadassah Ein Kerem Medical Center",
"city": "Jerusalem",
"state": "",
"country": "Israel",
"status": "",
"lat": 31.76904,
"lon": 35.21633
}
] | null | {
"compound": "AstroRx",
"targeting_mechanism": "Astrocyte-derived cell transplant to restore physiological capacity of malfunctioning astrocytes in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": "... | ||
NCT01016522 | Safety and Tolerability of the Ketogenic Diet in Amyotrophic Lateral Sclerosis (ALS) | PHASE3 | TERMINATED | INTERVENTIONAL | false | Johns Hopkins University | This research is being done to see if the ketogenic diet (which is high in fat and low in carbohydrates) is safe and tolerable in amyotrophic lateral sclerosis (ALS) patients who are fed through a gastrostomy tube. This is not a study to see if ketogenic diets are effective in the treatment of ALS. | [
{
"type": "DIETARY_SUPPLEMENT",
"name": "KetoCal"
}
] | 2009-11 | https://clinicaltrials.gov/study/NCT01016522 | [
"metabolic_dysfunction_ketone_metabolism"
] | [
{
"facility": "Johns Hopkins ALS Clinic",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | null | {
"compound": "KetoCal",
"targeting_mechanism": "Unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT04406675 | Social Cognition in Patients With Amyotrophic Lateral Sclerosis | NA | COMPLETED | INTERVENTIONAL | false | University Hospital, Angers | Amyotrophic Lateral Sclerosis, also known as Charcot disease, is a neurodegenerative disease evidenced by gradual paralysis of the muscles involved in voluntary motor function. The clinical hallmark of Amyotrophic Lateral Sclerosis is the combination of upper and lower motor neuron signs and symptoms. The most recent s... | [
{
"type": "OTHER",
"name": "neuropsychological test"
}
] | 2020-09-21 | https://clinicaltrials.gov/study/NCT04406675 | [] | [
{
"facility": "CHU Angers",
"city": "Angers",
"state": "Angers",
"country": "France",
"status": "",
"lat": 47.47156,
"lon": -0.55202
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04749433 | Study of [11C]CPPC to Assess the Safety and Tolerability in Patients With ALS | PHASE1 | TERMINATED | INTERVENTIONAL | false | Johns Hopkins University | The goal of this study is to evaluate the safety of using the \[5-cyano-N-(4-(4-\[11C\]Methylpiperazin-1-yl)-2-(Piperidin-1-yl)Phenyl)Furan-2-carboxamide\] (\[11C\]CPPC) radiotracer in positron emission tomography (PET) imaging of people with amyotrophic lateral sclerosis (ALS). The investigators are also interested to... | [
{
"type": "DRUG",
"name": "[11C]CPPC Injection"
}
] | 2021-09-01 | https://clinicaltrials.gov/study/NCT04749433 | [
"Sigma-1 receptor"
] | [
{
"facility": "Johns Hopkins Outpatient Center",
"city": "Baltimore",
"state": "Maryland",
"country": "United States",
"status": "",
"lat": 39.29038,
"lon": -76.61219
}
] | null | {
"compound": "[11C]CPPC",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00160004 | The Effect of Intensive Controlled Exercise in the Early Stages of Amyotrophic Lateral Sclerosis | PHASE1, PHASE2 | TERMINATED | INTERVENTIONAL | false | Radboud University Medical Center | Amyotrophic Lateral Sclerosis (ALS) is a progressive neurological disorder characterized by amongst others asymmetric muscle weakness, respiratory insufficiency and spasticity. The disease is usually fatal within 2-3 years and until now there is no cure. ALS patients are usually supported by a multidisciplinary team. O... | [
{
"type": "BEHAVIORAL",
"name": "Intensive Controlled Exercise"
}
] | 2006-03 | https://clinicaltrials.gov/study/NCT00160004 | [] | [
{
"facility": "Department of Allied health Occupations, Radboud University Nijmegen Medical Centre",
"city": "Nijmegen",
"state": "Gelderland",
"country": "Netherlands",
"status": "",
"lat": 51.8425,
"lon": 5.85278
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT02463825 | A Registry-Based Clinical Trial of Pimozide in Patients With Neuromuscular Junction Transmission Dysfunction Due to ALS | PHASE2 | UNKNOWN | INTERVENTIONAL | false | University of Calgary | Amyotrophic lateral sclerosis (ALS) is a neuromuscular disease that results in rapid decline in normal muscle function and tone leading to difficulties with mobility, eating, drinking, breathing, sleeping, and communicating. The disease is progressive and no cure currently exists. Most people diagnosed with ALS succumb... | [
{
"type": "DRUG",
"name": "Pimozide 2 mg per day"
},
{
"type": "DRUG",
"name": "Pimozide 4 mg per day"
},
{
"type": "DRUG",
"name": "Placebo (Lactose tablet)"
}
] | 2015-04 | https://clinicaltrials.gov/study/NCT02463825 | [
"neuromuscular_junction_transmission"
] | [
{
"facility": "South Health Campus",
"city": "Calgary",
"state": "Alberta",
"country": "Canada",
"status": "",
"lat": 51.05011,
"lon": -114.08529
}
] | null | {
"compound": "Pimozide",
"targeting_mechanism": "Blocks calcium channels to stabilize neuromuscular transmission.",
"targeting_mechanism_pmid": "29202456",
"animal_results": "Pimozide rescues neuromuscular transmission defects in C. elegans and zebrafish ALS models and stabilizes NMJ function in mice.",
"ani... | ||
NCT01259050 | Safety Study of High Doses of Zinc in ALS Patients | PHASE1, PHASE2 | COMPLETED | INTERVENTIONAL | false | Phoenix Neurological Associates, LTD | The purpose of this study is to determine the safety of Zinc given at 90mg/d in conjunction with 2mg/d of copper in ALS patients. | [
{
"type": "DRUG",
"name": "Zinc and Copper"
}
] | 2010-10 | https://clinicaltrials.gov/study/NCT01259050 | [
"zinc",
"copper"
] | [
{
"facility": "Phoenix Neurological Associates",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
}
] | null | {
"compound": "Zinc and Copper",
"targeting_mechanism": "Copper supplementation to restore copper dyshomeostasis and support SOD1 function in motor neurons.",
"targeting_mechanism_pmid": "27357743",
"animal_results": "Endogenous copper in the central nervous system fails to meet the elevated requirement for cop... | ||
NCT03020797 | A Clinical Trial to Evaluate the Safety and Efficacy of Fycompa in Subjects With Amyotrophic Lateral Sclerosis (ALS) | NA | TERMINATED | INTERVENTIONAL | false | Stony Brook University | This is a pilot trial to test perampanel (Fycompa; Eisai, Inc.) in ALS patients. The investigators will focus on safety and preliminary signs of efficacy. Perampanel is approved by the FDA for treatment of seizures in patients with epilepsy. In this study, perampanel will be used off-label for adults with ALS at an ora... | [
{
"type": "DRUG",
"name": "Perampanel"
},
{
"type": "DRUG",
"name": "Placebo Oral Tablet"
}
] | 2017-01-12 | https://clinicaltrials.gov/study/NCT03020797 | [
"glutamate_excitotoxicity"
] | [
{
"facility": "Stony Brook University Medical Center",
"city": "Stony Brook",
"state": "New York",
"country": "United States",
"status": "",
"lat": 40.92565,
"lon": -73.14094
}
] | null | {
"compound": "Perampanel",
"targeting_mechanism": "AMPA receptor antagonist that reduces glutamate excitotoxicity in motor neurons.",
"targeting_mechanism_pmid": "29453960",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04514952 | Individual Patient Expanded Access IND of Autologous HBadMSCs for the Treatment of Amyotrophic Lateral Sclerosis | Expanded Access | NO_LONGER_AVAILABLE | EXPANDED_ACCESS | true | Hope Biosciences Research Foundation | The drug for this submission is Hope Biosciences' autologous, adipose-derived culture-expanded mesenchymal stem cells (HB-adMSCs) for the treatment of a single patient with Amyotrophic Lateral Sclerosis (ALS). Stem cells have become a promising tool for the treatment of inflammatory and neurodegenerative conditions, in... | [
{
"type": "BIOLOGICAL",
"name": "HB-adMSCs"
}
] | https://clinicaltrials.gov/study/NCT04514952 | [
"neuroinflammation"
] | [
{
"facility": "River Oaks Hospital and Clinics",
"city": "Houston",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 29.76328,
"lon": -95.36327
}
] | null | {
"compound": "HB-adMSCs",
"targeting_mechanism": "Autologous adipose-derived mesenchymal stem cells that modulate neuroinflammation and provide neuroprotection through paracrine effects.",
"targeting_mechanism_pmid": "28872464",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "no... | |||
NCT03516994 | Reducing Disparities in the Quality of Advance Care Planning for Older Adults | NA | COMPLETED | INTERVENTIONAL | false | Duke University | This study compares the effectiveness of two different approaches to advance care planning among older African Americans and older Whites living in the community. The two approaches are a structured approach with an advance care planning conversation led by a trained person using Respecting Choices (First Steps) and a ... | [
{
"type": "BEHAVIORAL",
"name": "Respecting Choices First Steps"
},
{
"type": "BEHAVIORAL",
"name": "Five Wishes Form"
}
] | 2018-08-01 | https://clinicaltrials.gov/study/NCT03516994 | [] | [
{
"facility": "University of Alabama at Birmingham",
"city": "Birmingham",
"state": "Alabama",
"country": "United States",
"status": "",
"lat": 33.52066,
"lon": -86.80249
},
{
"facility": "Emory University",
"city": "Atlanta",
"state": "Georgia",
"country": "United St... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT04987671 | Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS | PHASE1, PHASE2 | UNKNOWN | INTERVENTIONAL | false | Amylyx Pharmaceuticals Inc. | The purpose of this study is to evaluate the pharmacokinetic and pharmacodynamic effect after a single dose or at steady state after multiple doses of AMX0035 in adults with sporadic ALS. | [
{
"type": "DRUG",
"name": "AMX0035"
}
] | 2021-08-05 | https://clinicaltrials.gov/study/NCT04987671 | [
"neuroinflammation",
"oxidative_stress"
] | [
{
"facility": "Norman Fixel Institute for Neurological Diseases",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
}
] | null | {
"compound": "AMX0035",
"targeting_mechanism": "Combination agent that targets oxidative stress and neuroinflammation pathways in motor neuron degeneration.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmi... | ||
NCT01160263 | Study of Dopamine and Serotonin Transporters in Patients With Amyotrophic Lateral Sclerosis and Controls | PHASE3 | COMPLETED | INTERVENTIONAL | false | Assistance Publique - Hôpitaux de Paris | The purpose of this study is to study the transporters of serotonin and dopamine in ALS patients in relation with the clinical phenotype, i.e., patients without stiffness, patients with pyramidal stiffness, patients with mixed (pyramidal and extra pyramidal) stiffness.
For such a goal the investigators will use SPECT ... | [
{
"type": "DRUG",
"name": "SPECT : 123 I-FP-CIT (DATSCAN) and 123I-ADAM"
}
] | 2012-10 | https://clinicaltrials.gov/study/NCT01160263 | [
"Dopamine transporter",
"Serotonin transporter"
] | [
{
"facility": "Salpêtrière Hospital",
"city": "Paris",
"state": "",
"country": "France",
"status": "",
"lat": 48.85341,
"lon": 2.3488
},
{
"facility": "Bretonneau Hospital",
"city": "Tours",
"state": "",
"country": "France",
"status": "",
"lat": 47.39484,
... | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00613899 | Feasibility of Telesurveillance and Home Cough Assistance for Amyotrophic Lateral Patients (ALS) | PHASE4 | COMPLETED | INTERVENTIONAL | false | Fondazione Salvatore Maugeri | The investigators want to test feasibility of a structured program of telesurveillance and home cough assistance for ALS patients. | [
{
"type": "OTHER",
"name": "telesurveillance"
}
] | 2007-10 | https://clinicaltrials.gov/study/NCT00613899 | [] | [
{
"facility": "Michele Vitacca",
"city": "Lumezzane",
"state": "BS",
"country": "Italy",
"status": "",
"lat": 45.64789,
"lon": 10.26487
}
] | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT03679975 | Riluzole Oral Soluble Film (ROSF) Swallowing Safety in Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | TERMINATED | INTERVENTIONAL | false | Aquestive Therapeutics | The primary objective is to evaluate the effect, if any, of a single 50 mg dose of Riluzole Oral Soluble Film (ROSF) on swallowing safety in individuals with amyotrophic lateral sclerosis. | [
{
"type": "DRUG",
"name": "Riluzole Oral Soluble film (ROSF) 50 mg"
}
] | 2018-04-04 | https://clinicaltrials.gov/study/NCT03679975 | [
"riluzole"
] | [
{
"facility": "University of Florida Center for Movement Disorders & Neuroscience",
"city": "Gainesville",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 29.65163,
"lon": -82.32483
}
] | null | {
"compound": "Riluzole Oral Soluble Film (ROSF) 50 mg",
"targeting_mechanism": "Riluzole is a benzothiazole derivative that blocks glutamatergic neurotransmission in the CNS by decreasing presynaptic glutamate release and increasing glutamate reuptake, exerting neuroprotective effects.",
"targeting_mechanism_pmi... | ||
NCT03755167 | A Follow up Study to Protocol 101/2 - Continued Treatment by IPL344 IV | PHASE2 | SUSPENDED | INTERVENTIONAL | false | Immunity Pharma Ltd. | This is a prospective, open-label, follow up study to protocol 101/2 - continued treatment by IPL344 IV administered once a day in up to 15 participants with ALS.
The study is designed to determine the safety, tolerability and initial efficacy of IPL344, administered once a day, by IV infusion for up to 36 months | [
{
"type": "DRUG",
"name": "IPL344"
}
] | 2018-12-09 | https://clinicaltrials.gov/study/NCT03755167 | [
"ipl344"
] | [
{
"facility": "Hadassah Medical Center/Neuromuscular / EMG service and ALS / Motor Neuron Disease Clinic",
"city": "Jerusalem",
"state": "",
"country": "Israel",
"status": "",
"lat": 31.76904,
"lon": 35.21633
},
{
"facility": "Hadassah Medical Center -Motor Neuron Disease Clinic"... | null | {
"compound": "IPL344",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT07193953 | Intravenous Immunoglobulin (IVIG) and Blood-Brain Barrier Disruption in Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | ACTIVE_NOT_RECRUITING | INTERVENTIONAL | false | Sunnybrook Health Sciences Centre | The goal of this study is to evaluate the safety and feasibility of IVIg administration in conjunction with primary motor cortex BBB opening using the Next Generation Dome Helmet (NGDH) FUS in adult participants with ALS. | [
{
"type": "DEVICE",
"name": "Next Generation Dome Helmet Focused Ultrasound"
},
{
"type": "DRUG",
"name": "Intravenous immunoglobulin (IVIG), 10% solution for infusion"
},
{
"type": "DRUG",
"name": "Definity® Vial for (Perflutren Lipid Microsphere) Injectable Suspension"
}
] | 2025-04-15 | https://clinicaltrials.gov/study/NCT07193953 | [
"neuroinflammation"
] | [
{
"facility": "Sunnybrook Health Sciences Centre",
"city": "Toronto",
"state": "Ontario",
"country": "Canada",
"status": "",
"lat": 43.70643,
"lon": -79.39864
}
] | null | {
"compound": "Intravenous immunoglobulin (IVIG)",
"targeting_mechanism": "IVIG administration in conjunction with blood-brain barrier opening via focused ultrasound to address neuroinflammation in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_fro... | ||
NCT06676423 | Evaluate the Safety of Neuronata-R® Inj. Suspended With HypoTHermosol® FRS (HTS-FRS) in Patients With ALS | PHASE1 | COMPLETED | INTERVENTIONAL | false | Corestemchemon, Inc. | This clinical trial is a single-center, open-label, and phase I clinical trial to Evaluate the Safety of Neuronata-R® Inj. suspended with HypoTHermosol® FRS (HTS-FRS) in Patients with Amyotrophic Lateral Sclerosis. | [
{
"type": "BIOLOGICAL",
"name": "Lenzumestrocel"
},
{
"type": "DRUG",
"name": "Riluzole"
}
] | 2022-11-09 | https://clinicaltrials.gov/study/NCT06676423 | [
"riluzole"
] | [
{
"facility": "Hanyang university hospital",
"city": "Seoul",
"state": "",
"country": "South Korea",
"status": "",
"lat": 37.566,
"lon": 126.9784
}
] | null | {
"compound": "Lenzumestrocel",
"targeting_mechanism": "Transplantation of human neural progenitor cells secreting GDNF to provide neurotrophic support and neuroprotection to degenerating motor neurons.",
"targeting_mechanism_pmid": "36064599",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurp... | ||
NCT05151471 | Efficacy and Safety Extension Study of Oral Edaravone Administered in Subjects With ALS | PHASE3 | TERMINATED | INTERVENTIONAL | false | Shionogi | To evaluate and compare the efficacy of two dosing regimens of oral edaravone in subjects with amyotrophic lateral sclerosis (ALS), based on the time from the randomization date in Study MT-1186-A02 to at least a 12-point decrease in Revised ALS Functional Rating Score (ALSFRS-R) or death, whichever happens first, over... | [
{
"type": "DRUG",
"name": "MT-1186"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-01-11 | https://clinicaltrials.gov/study/NCT05151471 | [
"oxidative_stress"
] | [
{
"facility": "Woodland Research Northwest, LLC",
"city": "Rogers",
"state": "Arkansas",
"country": "United States",
"status": "",
"lat": 36.33202,
"lon": -94.11854
},
{
"facility": "UF Health Cancer Center/Clinical Trials Office",
"city": "Gainesville",
"state": "Florida... | null | {
"compound": "MT-1186 (oral edaravone)",
"targeting_mechanism": "Edaravone blocks oxidative stress and free radical generation to exert neuroprotective effects in ALS.",
"targeting_mechanism_pmid": "38473944",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurpos... | ||
NCT06351592 | First in Human (FIH) Study of ALN-SOD in Adult Participants With Amyotrophic Lateral Sclerosis Associated With Mutation in the SOD1 Gene (SOD1-ALS) | PHASE1, PHASE2 | RECRUITING | INTERVENTIONAL | false | Regeneron Pharmaceuticals | This study is researching an experimental drug called ALN-SOD (called "study drug"). This study is focused on people with Amyotrophic Lateral Sclerosis (ALS) caused by a change in a gene called the Superoxide Dismutase-1 (SOD1) gene. This type of ALS is known as "SOD1-ALS". This is the first time that ALN-SOD will be g... | [
{
"type": "DRUG",
"name": "ALN-SOD"
},
{
"type": "OTHER",
"name": "Diluent"
},
{
"type": "DRUG",
"name": "Placebo (PB)"
}
] | 2024-08-28 | https://clinicaltrials.gov/study/NCT06351592 | [
"SOD1"
] | [
{
"facility": "Concord Repatriation General Hospital",
"city": "Concord",
"state": "New South Wales",
"country": "Australia",
"status": "RECRUITING",
"lat": -33.84722,
"lon": 151.10381
},
{
"facility": "Macquarie University",
"city": "Sydney",
"state": "New South Wales",
... | 844-734-6643 | clinicaltrials@regeneron.com | null | {
"compound": "ALN-SOD",
"targeting_mechanism": "ALN-SOD is an RNA interference agent targeting mutant SOD1 mRNA to reduce expression of pathogenic SOD1 protein in SOD1-ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repu... |
NCT05884034 | Effects of a Self-care Educational Program Via Telerehabilitation in Caregivers | NA | UNKNOWN | INTERVENTIONAL | false | Universidade Federal do Rio Grande do Norte | The purpose of this study is to evaluate the effects of a self-care educational program via telerehabilitation on the quality of life, burden, stress, pain, and depression of caregivers of people with ALS. | [
{
"type": "OTHER",
"name": "Telerehabilitation"
},
{
"type": "OTHER",
"name": "Education"
}
] | 2023-06 | https://clinicaltrials.gov/study/NCT05884034 | [] | [
{
"facility": "Federal University of Rio Grande do Norte",
"city": "Natal",
"state": "Rio Grande do Norte",
"country": "Brazil",
"status": "",
"lat": -5.795,
"lon": -35.20944
}
] | +55 84 8117-5502 | Raquel.lindquist@ufrn.br | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT01142856 | Mesenchymal Stem Cells for Treatment of Amyotrophic Lateral Sclerosis (ALS) | PHASE1 | COMPLETED | INTERVENTIONAL | false | Mayo Clinic | The purpose of this study is to determine the safety of injecting mesenchymal stem cells through intraspinal delivery for the treatment of ALS. | [
{
"type": "BIOLOGICAL",
"name": "autologous mesenchymal stem cells"
}
] | 2010-06 | https://clinicaltrials.gov/study/NCT01142856 | [] | [
{
"facility": "Mayo Clinic",
"city": "Rochester",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.02163,
"lon": -92.4699
}
] | null | {
"compound": "autologous mesenchymal stem cells",
"targeting_mechanism": "Mesenchymal stem cells differentiate into support cells and produce growth factors and anti-inflammatory cytokines to provide neuroprotection and trophic support to degenerating motor neurons.",
"targeting_mechanism_pmid": "32043626",
"a... | ||
NCT05281484 | Three Intermediate Expanded Access Protocols (EAP) CNMAu8.EAP01, CNMAu8.EAP02, and CNMAu8.EAP06 for ALS | Expanded Access | AVAILABLE | EXPANDED_ACCESS | true | Clene Nanomedicine | The primary objective of the intermediate expanded access protocol is to provide access to the investigational product, CNM-Au8, to up to 300 people living with ALS (pALS).
No formal clinical hypotheses are being evaluated with concurrent controls.
Secondary objectives include assessment of the safety of CNM-Au8 trea... | [
{
"type": "DRUG",
"name": "CNM-Au8"
}
] | https://clinicaltrials.gov/study/NCT05281484 | [
"cnm_au8"
] | [
{
"facility": "Barrow Neurological Institute (Enrollment is full, not recruiting)",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "AVAILABLE",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "UC Irvine (Enrollment is full, not recruiting)",
... | (801)676-9695 | eap@clene.com | null | {
"compound": "CNM-Au8",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | |
NCT01424176 | Dexpramipexole Renal PK Study | PHASE1 | COMPLETED | INTERVENTIONAL | false | Knopp Biosciences | This is a multicenter, open-label, single-dose, PK and safety study in subjects with various stages of renal impairment. | [
{
"type": "DRUG",
"name": "Dexpramipexole (dose 1)"
},
{
"type": "DRUG",
"name": "Dexpramipexole (dose 2)"
}
] | 2011-07 | https://clinicaltrials.gov/study/NCT01424176 | [
"dexpramipexole"
] | [
{
"facility": "Research Site",
"city": "Orlando",
"state": "Florida",
"country": "United States",
"status": "",
"lat": 28.53834,
"lon": -81.37924
},
{
"facility": "Research Site",
"city": "Brooklyn Center",
"state": "Minnesota",
"country": "United States",
"status... | null | {
"compound": "Dexpramipexole",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00021697 | Safety/Efficacy of AVP-923 in the Treatment of Emotional Lability (Uncontrolled Crying & Laughing) in Patients With ALS | PHASE3 | COMPLETED | INTERVENTIONAL | false | Avanir Pharmaceuticals | The purpose of this study is to compare and evaluate the safety of AVP-923 (dextromethorphan/quinidine) for the treatment of emotional lability in ALS patients. | [
{
"type": "DRUG",
"name": "AVP-923"
}
] | 2001-01 | https://clinicaltrials.gov/study/NCT00021697 | [
"dextromethorphan"
] | [
{
"facility": "Loma Linda University Dept. of Neurology",
"city": "Loma Linda",
"state": "California",
"country": "United States",
"status": "",
"lat": 34.04835,
"lon": -117.26115
},
{
"facility": "UCLA School of Medicine Dept. of Neurology",
"city": "Los Angeles",
"state... | null | {
"compound": "AVP-923 (dextromethorphan/quinidine)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT06207591 | Investigation on the Cortical Communication System | NA | RECRUITING | INTERVENTIONAL | false | UMC Utrecht | The goal of this clinical trial is to demonstrate communication through a brain implant in people in locked-in state, i.e. people with severe paralysis and communication problems.
The main questions it aims to answer are efficient and stable control of Brain-Computer interface (BCI) functions for communication with at... | [
{
"type": "DEVICE",
"name": "ECoG (electrocorticography) sensing"
}
] | 2023-12-15 | https://clinicaltrials.gov/study/NCT06207591 | [] | [
{
"facility": "University Medical Center",
"city": "Utrecht",
"state": "",
"country": "Netherlands",
"status": "RECRUITING",
"lat": 52.09083,
"lon": 5.12222
}
] | +31887555121 | neuroprothese@umcutrecht.nl | null | {
"compound": "unknown",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
NCT06769620 | A First in Human Study of ORT247 in Healthy Volunteers | PHASE1 | COMPLETED | INTERVENTIONAL | false | Orthogonal Neuroscience Inc. | This is a single center, double-blinded, randomized, placebo controlled single ascending dose clinical study, with the primary purpose of evaluating the safety, tolerability, pharmacokinetics (PK), and immunohistochemistry of escalating intravenous doses of ORT247 in healthy volunteers. | [
{
"type": "DRUG",
"name": "ORT247"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2022-06-06 | https://clinicaltrials.gov/study/NCT06769620 | [
"ort247"
] | [
{
"facility": "Worldwide Clinical Trials",
"city": "San Antonio",
"state": "Texas",
"country": "United States",
"status": "",
"lat": 29.42412,
"lon": -98.49363
}
] | null | {
"compound": "ORT247",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT00818389 | Study to Investigate the Safety and Efficacy of Lithium in Volunteers With Amyotrophic Lateral Sclerosis (ALS) | PHASE2, PHASE3 | TERMINATED | INTERVENTIONAL | false | Massachusetts General Hospital | The purpose of this study is to compare the effectiveness of lithium combined with riluzole to riluzole combined with placebo in people with amyotrophic lateral sclerosis. | [
{
"type": "DRUG",
"name": "Lithium Carbonate"
},
{
"type": "DRUG",
"name": "Riluzole"
},
{
"type": "DRUG",
"name": "placebo"
}
] | 2009-01 | https://clinicaltrials.gov/study/NCT00818389 | [
"lithium",
"riluzole"
] | [
{
"facility": "Phoenix Neurological Assoc., 1331 N. 7th Street, Suite 350",
"city": "Phoenix",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.44838,
"lon": -112.07404
},
{
"facility": "Cedars-Sinai ALS Center, Neurology Specialty Clinic, 8730 Alden Drive,... | null | {
"compound": "Lithium Carbonate",
"targeting_mechanism": "Lithium inhibits glycogen synthase kinase-3 (GSK-3), reducing neuroinflammation and promoting neuroprotection in ALS.",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurpos... | ||
NCT03034317 | NeuRx Diaphram Pacing System (DPS) Use in Amyotrophic Lateral Sclerosis (ALS) | NA | WITHDRAWN | INTERVENTIONAL | false | Synapse Biomedical | The purpose of this research study is to collect more information about the use, safety, and effectiveness of the NeuRx DPS® in ALS patients. | [
{
"type": "DEVICE",
"name": "NeuRx DPS"
}
] | 2017-02-02 | https://clinicaltrials.gov/study/NCT03034317 | [] | [] | null | {
"compound": "NeuRx DPS (Diaphragm Pacing System)",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} | ||
NCT06609213 | Oral Intake of Enteral Nutrition Formula Preceding Placement and Feeding Via GTube and Its Impact on Formula Intolerance in pALS | NA | RECRUITING | INTERVENTIONAL | false | Andrea Charvet | The main objective of the proposed study is to evaluate if oral intake of EN formula preceding Gtube placement will impact tolerance upon placement and feeding via Gtube in pALS. This single arm intervention study all participants will receive the intervention and researchers will utilize validated indicators combined ... | [
{
"type": "OTHER",
"name": "Medical Food"
}
] | 2025-01-10 | https://clinicaltrials.gov/study/NCT06609213 | [] | [
{
"facility": "Nova Southeastern University, Cathy J, Husman ALS Center",
"city": "Fort Lauderdale",
"state": "Florida",
"country": "United States",
"status": "RECRUITING",
"lat": 26.12231,
"lon": -80.14338
}
] | 954-262-6901 | acharve1@nova.edu | null | {
"compound": "Medical Food",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "not repurposed",
"repurposed_from_pmid": ""
} |
NCT01281631 | A Study of NP001 in Subjects With Amyotrophic Lateral Sclerosis (ALS) | PHASE2 | COMPLETED | INTERVENTIONAL | false | Neuraltus Pharmaceuticals, Inc. | This is a Phase 2 randomized, double-blind, placebo-controlled, multicenter study of NP001 in subjects with ALS. | [
{
"type": "DRUG",
"name": "NP001"
},
{
"type": "DRUG",
"name": "NP001"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2011-02 | https://clinicaltrials.gov/study/NCT01281631 | [
"np001"
] | [
{
"facility": "Mayo Clinic, Scottsdale",
"city": "Scottsdale",
"state": "Arizona",
"country": "United States",
"status": "",
"lat": 33.50921,
"lon": -111.89903
},
{
"facility": "UC, Irvine",
"city": "Irvine",
"state": "California",
"country": "United States",
"sta... | null | {
"compound": "NP001",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} | ||
NCT05795907 | Single & Multiple Ascending Dose Study of SAR443820 in Healthy Adult Participants | PHASE1 | COMPLETED | INTERVENTIONAL | false | Sanofi | This is a Phase 1, single-center study conducted in 2 parts:
Part 1a, single ascending dose (SAD-TDU16519): Double-blind, randomized, placebo-controlled sequential ascending single oral doses including up to 6 cohorts. Each cohort will include 8 participants (6 receiving SAR443820 and 2 placebo).
Part 1b (TDU16519): ... | [
{
"type": "DRUG",
"name": "SAR443820"
},
{
"type": "DRUG",
"name": "Placebo"
}
] | 2020-11-30 | https://clinicaltrials.gov/study/NCT05795907 | [
"sar443820"
] | [
{
"facility": "Prism Research-Site Number:8400001",
"city": "Saint Paul",
"state": "Minnesota",
"country": "United States",
"status": "",
"lat": 44.94441,
"lon": -93.09327
}
] | null | {
"compound": "SAR443820",
"targeting_mechanism": "unknown",
"targeting_mechanism_pmid": "",
"animal_results": "unknown",
"animal_results_pmid": "",
"repurposed_from": "unknown",
"repurposed_from_pmid": ""
} |
Subsets and Splits
No community queries yet
The top public SQL queries from the community will appear here once available.